IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Phase 3

• Conditions: Cancer Pain
• Interventions: Drug: Hydromorphone Hydrochloride Injection; Drug: Morphine Sulfate Sustained-release Tablets

• Registration Number: NCT04785768
• Lead Sponsor: Fujian Cancer Hospital

Brief Summary

Based on the previous HMORCT09-2, the results show that IV PCA for analgesia maintenance improvements control of severe cancer pain after successful titration. Therefore, a study is planned to further explore the difference of efficacy and safety between PCA with continuous + bolus dose versus bolus-only.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-02
• Study First Submitted: 2021-03-03
• Study First Submitted QC: 2021-03-05
• Last Update Submitted: 2021-03-05
• Study First Posted: 2021-03-08
• Last Update Posted: 2021-03-08
• Study Start: 2021-05-01
• Primary Completion: 2024-05-01
• Study Completion: 2024-07-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

1. The patients were 18-80 years old and diagnosed as malignant solid tumor by pathology;
2. Patients with persistent cancer pain and NRS score ≥ 7 during previous 24 hours;
3. Patients who did not receive radiotherapy, chemotherapy or targeted therapy within 7 days before randomization and trial；
4. Patients or his/her caregivers who are able to fill out the questionnaire forms ;
5. Ability to correctly understand and cooperate with medication guidance of doctors and nurses ;
6. Without psychiatric problems;
7. ECOG performance status ≤3;
8. Patients who did not receive the trial drug within 14 days before the trial；
9. The subjects voluntarily signed the informed consent.

Read More

Exclusion Criteria

1. The pain is confirmed not due to cancer;
2. Patients with severe post-operative pain;
3. Patients with paralytic ileus;
4. Patients with brain metastasis;
5. Patients hypersensitive to opioids;
6. Patients with abnormal lab results that have obvious clinical significance, such as creatine ≥ 2 fold of upper limit of normal value, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 fold of upper limit of normal value, or liver function of Child C grade;
7. Patients who cannot take drugs orally;
8. Patients with an incoercible nausea or vomiting;
9. Those who have received monoamine oxidase inhibitor (MAOI) within two weeks before randomization;
10. Patients who are pregnant or in lactation, or who plan to be pregnant within one month after the trial;
11. Alcoholic patients;
12. Patients with other conditions or reasons causing the patients unable to complete the clinical trial.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
PCA with continuous + bolus dose	Hydromorphone Hydrochloride Injection	（1）Intravenous PCA with hydromorphone after successful titration of 24 hours;（2）PCA hydromorphone with continuous infusion where dose/h was the total equianalgesic over the previous 24h divided by 24 and bolus dosage for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h；lockout time = 10 minutes；（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
PCA with bolus-only dose	Hydromorphone Hydrochloride Injection	（1）Intravenous PCA with hydromorphone after successful titration of 24 hours; (2)PCA hydromorphone with bolus-only where dosage was 10%-20% of the total equianalgesic over the previous 24h administrated as needed;（3）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day; (4)The treatment regimen was continued for 7 days.
Oral opioid	Morphine Sulfate Sustained-release Tablets	（1）Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours；(2)Oral sustained-released morphine where total equianalgesic over the previous 24h/2×75% every 12h/day and immediate-release morphine for breakthrough pain was 10%-20% of the total equianalgesic over the previous 24h； (3)Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；(4)The treatment regimen was continued for 7 days.

Primary Outcome Measures

Name	Time	Method
Mean pain score of days 1 to 3	up to 4 days	The Numerical Rating Scale (NRS, a score of 0 means no pain and 10 means the most severe) is used to assess the severity of pain. NRS of 24 hours is assessed every day. Mean pain score is a sum of average NRS of Day 1 (D 1) to Day 3 divided by 3 (the day of titration is defined as D0, the first day after titration is defined as D1, the second day after titration is defined as D2, and so on).
Number of Breakthrough cancer Pain (BTcP)	up to 4 days	Breakthrough cancer Pain (BTcP) is NRS \> 3

Secondary Outcome Measures

Name	Time	Method
Mean pain score of days 1 to 6	up to 7 days	Mean pain score is a sum of average NRS of D1 to D6 divided by 6

Trial Locations

Locations (1)

China, Fujian; 🇨🇳 Fuzhou, Fujian, China